BDO has a new report that examines Big Pharma's cuts to its R&D budget, and investigates the trade off between cutting internal R&D and filling the pipeline by doing deals with smaller firms.
(This is the subject of a research project that I hope to execute within the next year.)
Research and commentary from a former senior executive in the U.S. Department of Health & Human Services
No comments:
Post a Comment